September 23, 2024
TOPLINE: Black women in the United States have higher breast cancer (BC) mortality rates than White women across tumor subtypes. The greatest disparity in BC-specific survival […]
September 23, 2024
The Food and Drug Administration expanded the label of isatuximab-irfc (Sarclisa — Sanofi-Aventis) on September 20 to include treatment with bortezomib, lenalidomide, and dexamethasone for newly […]
September 23, 2024
The US Food and Drug Administration (FDA) has granted a second-line indication to amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in non–small-cell lung cancer (NSCLC). Amivantamab with carboplatin […]
September 23, 2024
(Reuters) -AstraZeneca said on Monday its experimental precision drug developed with Japan’s Daiichi Sankyo did not significantly improve overall survival for patients with a type of […]
September 20, 2024
The European Medicines Agency (EMA) has recommended granting marketing authorization for orphan medicine Hetronifly (serplulimab, Henlius Europe) to treat extensive stage small cell lung cancer (ES-SCLC). […]
September 20, 2024
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended the granting of marketing authorization for Hympavzi (marstacimab) for treating bleeding episodes […]
September 20, 2024
The European Medicines Agency (EMA) has determined that the medicinal product Elahere (mirvetuximab soravtansine, AbbVie Deutschland), indicated for the treatment of adults with folate receptor alpha […]
September 20, 2024
BARCELONA, Spain — Antibody-drug conjugates (ADCs) could address significant challenges in ovarian cancer treatment, as highlighted in a session at the European Society for Medical Oncology […]
September 20, 2024
BARCELONA, SPAIN — Patients with high-risk stage III resectable melanoma treated with neoadjuvant combination immunotherapy achieved higher event- and recurrence-free survival than patients who received monotherapy […]